Literature DB >> 19543427

The burden of prostate cancer in Canada.

Yves Fradet1, Laurence Klotz, John Trachtenberg, Alexandre Zlotta.   

Abstract

The clinical and economic burden of prostate cancer in Canada is substantial, and is rising. Studies indicate that 1 in 7 men will develop prostate cancer during their lifetime, and another 1 in 27 will die because of it. It is estimated that 4300 Canadian men will die of prostate cancer in 2008. Age, family history, race and diet are all risks associated with the development of prostate cancer. A diagnosis of cancer carries a significant burden and like other cancers is a cause of significant anxiety and depression. Uncertainty regarding the value of screening for prostate cancer has been, and continues to be, a challenge for primary care physicians and urologists.

Entities:  

Year:  2009        PMID： 19543427      PMCID： PMC2698782     

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  55 in total

1.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

2.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

3.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

4.  Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.

Authors:  Andrea Gallina; Nazareno Suardi; Francesco Montorsi; Umberto Capitanio; Claudio Jeldres; Fred Saad; Markus Graefen; Shahrokh F Shariat; Hugues Widmer; Philippe Arjane; François Péloquin; Paul Perrotte; Pierre I Karakiewicz
Journal:  Int J Cancer       Date:  2008-08-01       Impact factor: 7.396

5.  Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.

Authors:  Zhihong Gong; Ilir Agalliu; Daniel W Lin; Janet L Stanford; Alan R Kristal
Journal:  Cancer Causes Control       Date:  2007-09-30       Impact factor: 2.506

6.  Prostate cancer.

Authors:  David F Penson; June M Chan
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

Review 7.  Obesity, metabolic syndrome, and prostate cancer.

Authors:  Ann W Hsing; Lori C Sakoda; Streamson Chua
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

8.  Cancer mortality correlation studies--III: statistical associations with dietary selenium intakes.

Authors:  G N Schrauzer; D A White; C J Schneider
Journal:  Bioinorg Chem       Date:  1977

9.  Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up.

Authors:  I J Korfage; M-L Essink-Bot; A C J W Janssens; F H Schröder; H J de Koning
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

10.  High levels of untreated distress and fatigue in cancer patients.

Authors:  L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640
View more
  12 in total

1.  2018 CUA Abstracts.

Authors: 
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

2.  Age-standardized cancer-incidence trends in Canada, 1971-2015.

Authors:  Darren R Brenner; Yibing Ruan; Eileen Shaw; Dylan O'Sullivan; Abbey E Poirier; Emily Heer; Paul J Villeneuve; Stephen D Walter; Christine M Friedenreich; Leah Smith; Prithwish De
Journal:  CMAJ       Date:  2019-11-18       Impact factor: 8.262

3.  The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

Authors:  Alaina Garbens; Christopher J D Wallis; Rano Matta; Ronald Kodama; Sender Herschorn; Steven Narod; Robert K Nam
Journal:  Can Urol Assoc J       Date:  2018-12-03       Impact factor: 1.862

4.  Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening.

Authors:  James Dickinson; Amanda Shane; Marcello Tonelli; Sarah Connor Gorber; Michel Joffres; Harminder Singh; Neil Bell
Journal:  CMAJ Open       Date:  2016-03-02

5.  Prognostic factors for the development of biochemical recurrence after radical prostatectomy.

Authors:  Ahmed F Kotb; Ahmed A Elabbady
Journal:  Prostate Cancer       Date:  2011-06-15

6.  Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination.

Authors:  Stephen Odunayo Ikuerowo; Olufunmilade Adefolarin Omisanjo; Muftau Jimoh Bioku; Michael Olawale Ajala; Victor Patrick Nonyelim Mordi; Julius Olusanmi Esho
Journal:  Pan Afr Med J       Date:  2013-08-10

7.  Sunlight exposure during leisure activities and risk of prostate cancer in Montréal, Canada, 2005-2009.

Authors:  Jennifer Yu; Jérôme Lavoué; Marie-Élise Parent
Journal:  BMC Public Health       Date:  2014-07-28       Impact factor: 3.295

8.  Prostate cancer surveillance by occupation and industry: the Canadian Census Health and Environment Cohort (CanCHEC).

Authors:  Jeavana Sritharan; Jill MacLeod; Shelley Harris; Donald C Cole; Anne Harris; Michael Tjepkema; Paul A Peters; Paul A Demers
Journal:  Cancer Med       Date:  2018-03-01       Impact factor: 4.452

Review 9.  Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis.

Authors:  Leire Moya; Jonelle Meijer; Sarah Schubert; Farhana Matin; Jyotsna Batra
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

10.  The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.

Authors:  Margot K Davis; Jennifer L Rajala; Scott Tyldesley; Tom Pickles; Sean A Virani
Journal:  J Oncol       Date:  2015-08-02       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.